Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index; 24 of the 34 sources its claims cite were checked for support.
Abstract
BACKGROUND: Semaglutide, a glucagon-like peptide-1 receptor agonist, has been shown to reduce the risk of adverse cardiovascular events in patients with diabetes. Whether semaglutide can reduce cardiovascular risk associated with overweight and obesity in the absence of diabetes is unknown. METHODS: In a multicenter, double-blind, randomized, placebo-controlled, event-driven superiority trial, we enrolled patients 45 years of age or older who had preexisting cardiovascular disease and a body-mass index (the weight in kilograms divided by the square of the height in meters) of 27 or greater but no history of diabetes. Patients were randomly assigned in a 1:1 ratio to receive once-weekly subcutaneous semaglutide at a dose of 2.4 mg or placebo. The primary cardiovascular end point was a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke in a time-to-first-event analysis. Safety was also assessed. RESULTS: A total of 17,604 patients were enrolled; 8803 were assigned to receive semaglutide and 8801 to receive placebo. The mean (±SD) duration of exposure to semaglutide or placebo was 34.2±13.7 months, and the mean duration of follow-up was 39.8±9.4 months. A primary cardiovascular end-point event occurred in 569 of the 8803 patients (6.5%) in the semaglutide group and in 701 of the 8801 patients (8.0%) in the placebo group (hazard ratio, 0.80; 95% confidence interval, 0.72 to 0.90; P<0.001). Adverse events leading to permanent discontinuation of the trial product occurred in 1461 patients (16.6%) in the semaglutide group and 718 patients (8.2%) in the placebo group (P<0.001). CONCLUSIONS: In patients with preexisting cardiovascular disease and overweight or obesity but without diabetes, weekly subcutaneous semaglutide at a dose of 2.4 mg was superior to placebo in reducing the incidence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke at a mean follow-up of 39.8 months. (Funded by Novo Nordisk; SELECT ClinicalTrials.gov number, NCT03574597.).
Overview
CoChat Summary
## TL;DR
In this multicenter randomized trial of adults with preexisting cardiovascular disease, overweight or obesity, and no diabetes, weekly semaglutide 2.4 mg reduced major cardiovascular events versus placebo over a mean 39.8 months. The benefit came with more adverse-event-related discontinuation, especially gastrointestinal events.
## Key findings
- The primary composite cardiovascular end point occurred in 569/8803 (6.5%) semaglutide patients vs 701/8801 (8.0%) placebo patients (hazard ratio 0.80; 95% CI, 0.72 to 0.90; P<0.001).
- Mean body weight change over 104 weeks was -9.39% with semaglutide vs -0.88% with placebo, an estimated treatment difference of -8.51 percentage points (95% CI, -8.75 to -8.27).
- Adverse events leading to permanent discontinuation occurred in 1461 (16.6%) semaglutide patients vs 718 (8.2%) placebo patients (P<0.001); gastrointestinal disorders accounted for 880 (10.0%) vs 172 (2.0%).
- The paper reports fewer serious adverse events with semaglutide: 2941 (33.4%) vs 3204 (36.4%) (P<0.001), while gallbladder-related disorders were slightly higher: 246 (2.8%) vs 203 (2.3%) (P=0.04).
## Methods
- Multicenter, double-blind, randomized, placebo-controlled, event-driven superiority trial at 804 clinical sites in 41 countries.
- Enrolled 17,604 patients aged 45 years or older with BMI ≥27, established cardiovascular disease, and no history of diabetes; randomized 1:1 to weekly subcutaneous semaglutide 2.4 mg or placebo.
- Primary analysis was intention-to-treat time-to-first-event analysis using a Cox proportional hazards model; secondary end points were tested hierarchically.
## Limitations
- The paper states that it included only patients with preexisting cardiovascular disease, so effects on primary prevention in people with overweight/obesity but no prior atherosclerotic disease were not studied.
- The authors note the patient population was not globally representative, with 27.7% women and 3.8% Black persons enrolled.
- Evident from the report: although mean follow-up was 39.8 months, the x-axis in the figure is truncated at 48 months because of limited patients after that time, so very long-term effects are not fully established.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
17 Valid · 0 Not valid · 5 Not checked · 53 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Perivascular and epicardial adipose tissue impose direct adverse effects on the vascular endothelium and myocardium. 30”
What the sources say
- Partly supportedcites [30] 30. Iacobellis G. Epicardial adipose tissue in contemporary cardiology. Nat Rev Cardiol 2022; 19: 593-606. sourceExperimental — accuracy not yet measured
The Introduction says epicardial adipose tissue (EAT) can harm adjacent myocardium through inflammatory and profibrotic secretions, and the Coronary artery disease section says EAT secretes factors associated with increased endothelial permeability. The paper identifies pericoronary EAT around coronary arteries, but does not establish the claim for perivascular adipose tissue generally. It also describes EAT as protective under normal conditions, so the unqualified assertion of adverse effects overstates the source. These sections have no page numbers in our copy. (LLM, conf=0.85)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Semaglutide, a long-acting analogue of GLP-1, administered at a dose of 2.4 mg subcutaneously once weekly for 104 weeks, was found to reduce body weight by a mean of 15.2% among patients with overweight or obesity who did not have diabetes. 18”
What the sources say
- Supportedcites [18] 18. Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med 2022; 28: 2083-91. 19. Ryan DH, Lingvay I, Colhoun HM, et al. Semaglutide effects on cardiovascular outcomes in people with overweight or obesity (SELECT) rationale and design. Am Heart J 2020; 229: 61-9. source
The Methods (Procedures; page not provided) describe once-weekly subcutaneous semaglutide 2.4 mg for 104 weeks in addition to behavioral intervention. The Discussion reports a mean 15.2% weight loss at week 104 in adults with overweight or obesity without diabetes. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“and the 37.8-percentage-point decrease in the high-sensitivity C-reactive protein level with semaglutide in this trial is similar to that reported with statins. 36”
What the sources say
- Supportedcites [36] 36. Asher J, Houston M. Statins and C-reactive protein levels. J Clin Hypertens (Greenwich) 2007; 9: 622-8. source
The “CRP Reductions With Statins” section reports CRP reductions of 29% and 43% with atorvastatin monotherapy, making the citing trial’s 37.8-percentage-point decrease a reasonable comparison. The source notes that reductions vary by statin and regimen; it does not assess semaglutide itself. (LLM, conf=0.92)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Similarly, bariatric surgery, in which reductions in body weight of more than 20% can be achieved, has been associated with fewer cardiovascular events than usual care. 33,34”
What the sources say
- Partly supportedcites [33] 33. Mentias A, Aminian A, Youssef D, et al. Long-term cardiovascular outcomes after bariatric surgery in the Medicare population. J Am Coll Cardiol 2022; 79: 1429-37. sourceExperimental — accuracy not yet measured
The Results report fewer heart-failure hospitalizations, myocardial infarctions, and ischemic strokes after bariatric surgery than in the matched control group; the Discussion describes that group as managed conservatively. The Discussion says surgery induces substantial, sustained weight loss, but our copy does not give the claimed reduction of more than 20% of body weight. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [34] 34. Sjöström L, Peltonen M, Jacobson P, et al. Bariatric surgery and long-term cardiovascular events. JAMA 2012; 307: 56-65. source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In addition, reductions in excess abnormal body fat ameliorate the systemic proinflammatory and prothrombotic milieu associated with obesity. 31”
What the sources say
- Partly supportedcites [31] 31. Magkos F, Fraterrigo G, Yoshino J, et al. Effects of moderate and subsequent progressive weight loss on metabolic function and adipose tissue biology in humans with obesity. Cell Metab 2016; 23: 591-601. sourceExperimental — accuracy not yet measured
The Results and Discussion (page unavailable) report that 11%–16% weight loss was associated with reduced systemic inflammation, but 5% weight loss did not reduce circulating inflammatory markers. The paper does not report an improvement in a prothrombotic milieu, so it supports only the inflammatory part of the claim and only at the greater weight-loss levels studied. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
37 more claims · 6 with their cited sources checked
Create a free account to see all 75 claims and every source verdict.
- Probably not a substantial claim. 27
- It may state two separate claims as one. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“and, more recently, in people with obesity without diabetes [4].”
From Effects of GLP ‐1 Receptor Agonists and Dual GIP / GLP ‐1 Receptor Agonists on Inflammatory and Metabolic Biomarkers in Type 2 Diabetes: A Systematic Review and Meta‐Analysis (2026) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“People were able to maintain approximately 10% WL over a 4-year period, and the proportion of participants experiencing SAE during the trial was lower in those assigned to semaglutide 2.4 mg compared to placebo (33.4% vs. 36.4%).”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [110]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The SELECT trial is the first study providing long-term data on the safety and efficacy of semaglutide 2.4 mg [110].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [110]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The SELECT trial demonstrated a 20% reduction in MACE among patients with obesity and established cardiovascular disease [15,85].”
From Adherence and Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support—A Narrative Review (2026) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The findings of benefit on all cardiovascular outcomes and death due to any cause are consistent with the previous meta-analysis but are expanded in important ways including the demonstration of benefit in a population with chronic kidney disease, as well as people with overweight or obese and cardiovascular disease but without diabetes. 26,27”
From Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials (2025) · cites this paper as [27]
Experimental — accuracy not yet measured
71 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Health effects of overweight and obesity in 195 countries over 25 years
Collaborators, T. G. 2. O. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614362 · Cited by 7,918
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Self-citationSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Self-citationCholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
A Randomized Trial of Intensive versus Standard Blood-Pressure Control
The SPRINT Research Group (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1511939 · Cited by 6,325
Hubert, H. B., Feinleib, M., McNamara, P. M., & Castelli, W. P. (1983) · Circulation · doi:10.1161/01.cir.67.5.968 · Cited by 4,241
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes
The Look AHEAD Research Group (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1212914 · Cited by 2,908
Statistical Models Based on Counting Processes
Andersen, P. K., Borgan, Ø., Gill, R. D., & Keiding, N. (1993) · Springer Series in Statistics · doi:10.1007/978-1-4612-4348-9 · Cited by 2,855
Cited by
Items 2,101–2,200 of 3,116
Adiposity at the Core of Cardiometabolic Disease
Spatz, E. S. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.08.056 · Cited by 1
Qiu, L., Liu, J., & Hu, N. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1870649 · Cited by 4
“Reductions in body weight, waist circumference, blood pressure, in fl ammatory biomarkers and other risk factors likely contributed to bene fi t, but the absence of diabetes removes HbA1c lowering as a necessary explanation (6, 21).”
InfluentialGLP-1 Receptor Agonists: Advances in Mechanism, Therapeutic Applications, and Future Perspectives
Pawar, M., Patil, C. S., Fakir, J. S., Pagar, D. S., & Mahajan, S. K. (2025) · BioMed Target Journal · doi:10.59786/bmtj.322 · Cited by 1
Verlaan, J. P. L., van Es, N., & Scheres, L. J. J. (2025) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2025.07.035
Gan, S., Zhang, Q., Zhang, C. P., Li, Y., Yin, Y., Ma, H., & ZHANG, Z. (2026) · Biomolecules · doi:10.3390/biom16081093
“GLP-1RAs such as semaglutide, liraglutide, and dulaglutide, improved glycemic control and reduced major adverse cardiovascular events, with effects partly independent of weight loss [133–136].”
Obesity phenotyping at the “heart” of risk stratification
Sbraccia, P. (2024) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2024.04.005
GLP-1 receptor agonism in prostate cancer: insights and perspectives
Vignera, S. L., & Condorelli, R. A. (2026) · Endocrine Related Cancer · doi:10.1530/erc-26-0398
Zhu, S., Yang, F., Lu, H., Jiang, J., & He, W. Q. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1843719
“Semaglutide also has high-level evidence, as phase 3 data demonstrated significant histological benefit in MASH with F2 – F3 fibrosis, and GLP-1 receptor agonist therapy has additional evidence for cardiovascular risk reduction in high-risk obesity or diabetes population (154, 155).”
Alkhateeb, F. S. (2026) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-026-02716-x
Sullivan, S. D. (2026) · Annals of Internal Medicine · doi:10.7326/annals-26-01469
Effects of metabolic syndrome on cardiovascular outcomes in non-obese heart failure patients
Han, D. D., Miedlich, S. U., Morse, D. S., Block, R. C., Zaręba, W., Goldenberg, I., McNitt, S. A., & Kutyifa, V. (2026) · ESC Heart Failure · doi:10.1093/eschf/xvag073
“16,17 On the other hand, a lower BMI is not always beneficial.”
IDRIS, I. R. (2024) · Diabetes Obesity and Metabolism Now · doi:10.1002/doi2.70004
Kong, M., Zheng, Z., Huang, M., Huang, S., Zhao, X., Yang, Y., & Zhang, C. (2026) · MedComm · doi:10.1002/mco2.70869 · Cited by 1
Skacel, T. P., Saleh, N. R., Pavelec, C. M., Quach, K., Bradley, L. A., Bresticker, J. E., Patel, A. R., Wolf, M. J., & Epstein, F. H. (2026) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2026.101554 · Cited by 1
Campbell, C., Mansoor, M., Eley, C., Nann, S. D., & Puhalla, H. (2026) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2026.07.012 · Cited by 1
Repair and regeneration across the lifespan: an ontogenetic perspective
Barrera-saldaña, H. A., Fernández-Garza, L. E., Guillen-Silva, F., Fajardo‐Ramírez, Ó. R., Pavlovich, R. I., Gómez-Gallardo, F. V., Rodríguez-Fuentes, D. E., Avila-Villalobos, A. Y., Barrera‐Barrera, S. A., & Somoza, R. A. (2026) · Frontiers in Aging · doi:10.3389/fragi.2026.1888854 · Cited by 1
“GLP-1 receptor agonists merit inclusion in a longevity-oriented framework because of their established cardiovascular benefit in relevant populations and their favorable effects on adiposity, glycemic burden, blood pressure, and inflammatory tone (Lincoff et al., 2023; Liuzzo and Patrono, 2024).”
Lanthier, L., Langlois, M., Plourde, M.-É., et al. (2024) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2024.01.006
Mortada, I., Quach, V., Lee, A. W., Long, N., Ebel, G., Al‐Abdouh, A., Albayyaa, M., Love, A. N., Mansour, S., Chatila, K., et al. (2026) · Journal of the Society for Cardiovascular Angiography & Interventions · doi:10.1016/j.jscai.2026.105384
“15 Similarly, the Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction trial demonstrated that semaglutide improved symptoms, exercise capacity, and quality of life in patients with obesity-related heart failure with preserved ejection fraction, a phenotype highly relevant to…”
Adipositasleitlinie 2024 – was ist neu?
Hauner, H. (2024) · Adipositas - Ursachen Folgeerkrankungen Therapie · doi:10.1055/a-2340-0837
Letter to the Editor Regarding the SELECT Trial
Penteris, M., & Lampropoulos, K. (2025) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-025-07686-1
Nassiri, S., Handoko, M. L., van de Bovenkamp, A. A., van Empel, V. P. M., van Raalte, D. H., & Eringa, E. C. (2026) · Heart Failure Reviews · doi:10.1007/s10741-026-10671-x
Schiavon, C. A. (2024) · Obesity Surgery · doi:10.1007/s11695-024-07272-8
Diabetes and cancer: therapeutic implications
Fay, S., Bayshtok, G., HAMO, C. E., Butler, J., & Bloom, M. W. (2026) · Cardio-Oncology · doi:10.1186/s40959-025-00412-8
“Follow-up analyses also found fewer heart-failure-related events, including hospitalizations or urgent visits requiring intravenous therapy [55, 56].”
Adipositas und Herz: neue Medikamente und neue Strategien für Kardiologen
Hollstein, T. (2025) · Aktuelle Kardiologie · doi:10.1055/a-2606-7020
Kolaczynski, J. W., & Surmacz, E. (2025) · Exploration of Endocrine and Metabolic Diseases · doi:10.37349/eemd.2025.101449
Sind GLP-1-Rezeptor-Agonisten und SGLT2-Inhibitoren auch im höheren Lebensalter geeignet?
Stüdemann, S., & Engeli, S. (2025) · Adipositas - Ursachen Folgeerkrankungen Therapie · doi:10.1055/a-2492-9440
Dual GIP and GLP-1 agonists and changes in the lipid spectrum
Karásek, D. (2024) · Vnitřní lékařství · doi:10.36290/vnl.2024.006
Chan, Y.-C., Chuang, S., Wu, L.-C., Kuo, Y., Lian, Y.-Z., & Chen, Y. (2025) · The Journal of Arthroplasty · doi:10.1016/j.arth.2025.11.036 · Cited by 1
EndoBridge 2025: pearls and highlights
Yıldız, B. O., Armenti, M., Brandi, M. L., Carey, J., Carling, T., Ciudin, A., Dhatariya, K., Fountas, A., Frühbeck, G., Goulis, D. G., et al. (2026) · HORMONES · doi:10.1007/s42000-026-00804-0 · Cited by 1
Elbaz, M., Grazide, M.-H., Bataille, V., Blanc, G., Gautier, P., Mkhwananzi, R., Firat, H., & Vindis, C. (2026) · medRxiv · doi:10.64898/2026.03.04.26347626
GLP-1 receptor agonists in type 1 diabetes: a new frontier for cardiovascular prevention?
Chen, Q., Abuduhelili, B., Xiao, Y., Chen, Y., Xu, J., & Chen, C. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag371
Simeao, M. M. D. M., de Lima, C. F., Garcia, T. R., Rezende, I. R., de Carvalho, G. M., Guimarães, P. H. F., da Silva, M. O., Costa, G. M. E., GOMES, B. D. S. A., & Kovalski, T. P. (2026) · RECIMA21 - Revista Científica Multidisciplinar · doi:10.47820/recima21.v7i5.7887
GLP-1 Receptor Agonists in Hidradenitis Suppurativa: Time to Treat the Whole Patient
Burboa, G. U. V., & Guillén, M. Á. R. F. (2026) · Skin Appendage Disorders · doi:10.1159/000552598
Schmaling, K. B., & Kaplan, R. M. (2025) · Cambridge University Press eBooks · doi:10.1017/9781009391733.016
Authors reply: Obesity treatment in adolescents and adults in the era of personalized medicine
Sundbom, M., Järvholm, K., Sjögren, L., et al. (2025) · Journal of Internal Medicine · doi:10.1111/joim.20062
Bøgelund, M., Rasmussen, A. F., Andreassen, P., Nielsen, P., Stensen, S., & Bruun, J. M. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70474
Pan, S., Weng, C., Sheen, Y., Tsai, S.-F., Lin, J., Chen, J., Lin, C., Huang, S.-P., Chang, C.-J., Lin, H.-J., et al. (2026) · The American Journal of Medicine · doi:10.1016/j.amjmed.2026.06.023 · Cited by 1
Chronic kidney disease in metabolic syndrome
Вадимовна, В. С., & Звартау, Н. Э. (2025) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2025-6537 · Cited by 5
Incretins and the metabolic syndrome
Karásek, D. (2024) · Vnitřní lékařství · doi:10.36290/vnl.2024.020 · Cited by 1
Cho, D. (2026) · International Journal of Heart Failure · doi:10.36628/ijhf.2026.0002
“26) Although post hoc analyses suggested that approximately 33% of this benefit was mediated through reductions in waist circumference, a significant portion of the cardioprotective effect was independent of baseline adiposity and the magnitude of weight loss.”
Adeoye, O. O., Gesink, D., Dzyubak, O., Ferguson, S. E., & Kim, S. R. (2026) · Gynecologic Oncology Reports · doi:10.1016/j.gore.2026.102058 · Cited by 1
Guida, C., Hsu, F., Neiberg, R. H., Semelka, C., Chen, H., Kramer, P. A., Houston, D. K., Nicklas, B., Kritchevsky, S. B., & Miller, M. E. (2026) · GeroScience · doi:10.1007/s11357-026-02529-9
Obesity and heart failure—the role of GLP-1 receptor agonists
Simonis, G., & Schatz, U. (2025) · Herz · doi:10.1007/s00059-025-05312-2
Xu, S. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71138 · Cited by 2
Sánchez-López, D., García‐Vega, D., Viñuela, J. E., Ferreirós-Vidal, I., Iglesias-Álvarez, D., Martínez‐Comendador, J. M., Reija-López, L., Fernández-González, Á. L., González‐Juanatey, J. R., & Eiras-Penas, S. (2025) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2025.10.009
Potential missed opportunities to improve long-term liver allograft health
Fallahzadeh, M. A., McCaughan, G. W., & O’Leary, J. G. (2025) · Liver Transplantation · doi:10.1097/lvt.0000000000000720 · Cited by 2
Donoso, P. D. R. Q., Briones, R. F. Z., Castro, C. P. M., Narváez, D. L. B., Velasco, S. A., & Jimenez, S. N. C. (2026) · International Journal of Research in Medical Sciences · doi:10.18203/2320-6012.ijrms20261347
GLP-1 Receptor Agonists: A Paradigm Shift in Cardiovascular Prevention Beyond Diabetes
Almohammadi, A. A. (2026) · International Journal of Preventive Medicine · doi:10.4103/ijpvm.ijpvm_388_25 · Cited by 3
Tonnesen, P. T., Olesen, K. K. W., Gyldenkerne, C., Hansen, M. K., Stødkilde-Jørgensen, N., Thrane, P. G., Andersen, M. H., Poulsen, P. L., Thomsen, R. W., Sattar, N. A., et al. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-026-03085-4 · Cited by 1
“…criteria replicated those of the SELECT trial: BMI 27 kg/m 2 , diabetes, age below 45 years, end-stage renal disease, history of malignant neoplasms within five years before baseline, history of acute pancreatitis within 180 days before baseline, and history of chronic pancreatitis [15].”
InfluentialGLP-1 receptor agonism in cardiovascular disease prevention
Saleh, H. (2025) · Asia-Pacific Journal of Pharmacotherapy & Toxicology · doi:10.32948/ajpt.2024.11.22 · Cited by 1
A Future Without Excess Health Care Spending Growth?
Sahni, N. R., Ozisik, M. L., Cutler, D., & Emanuel, E. (2026) · JAMA · doi:10.1001/jama.2026.15970
CARDIOPROTECTIVE EFFECTS OF GLUCAGON-LIKE PEPTIDE-1 AGONISTS: A REVIEW OF RANDOMIZED CLINICAL TRIALS
Zaikina, Т. S., Рынчак, П. И., & Tytova, G. Y. (2026) · Bulletin of Problems Biology and Medicine · doi:10.29254/2077-4214-2026-2-181-62-67
Tseng, T., & Chang, R. (2026) · The American Journal of Medicine · doi:10.1016/j.amjmed.2026.09.010 · Cited by 1
Tian, X., Ma, X., Song, E., Li, X., Fu, W., He, H., Gao, Z., & Gao, B. (2026) · Translational research · doi:10.1016/j.trsl.2026.07.008
Ghuman, A., & Das, M. (2026) · Journal of the Society for Cardiovascular Angiography & Interventions · doi:10.1016/j.jscai.2026.105387 · Cited by 1
Murugadoss, K., Venkatakrishnan, A., & Soundararajan, V. (2026) · npj Metabolic Health and Disease · doi:10.1038/s44324-026-00131-3
Carretero‐Gómez, J., Rodríguez, J. M. F., Doña, A. M., Miramontes‐González, J. P., Soler, J. J. G., Soto, M. I. P., Carrasco-Sánchez, F. J., Gómez-Delgado, F., Arévalo‐Lorido, J. C., & Martínez, P. P. (2025) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2025.502352 · Cited by 1
Podcasts and Scientific Journals: We Need Both
Huseynova, R., Khasanova, S., Quiles‐Corona, M., et al. (2026) · Newborn · doi:10.5005/jp-journals-11002-0161
Peptide‐Based GLP‐1 Receptor Agonists for the Treatment of Type 2 Diabetes and Obesity
Kodra, J. T., Linderoth, L., Reedtz‐Runge, S., Kruse, T., & Kofoed, J. (2026) · Wiley eBooks · doi:10.1002/9783527845408.ch4
Reytor-González, C., Loor-Cedeño, A., Gavilanes, D. J., Matos, A., Parise-Vasco, J. M., Angamarca-Iguago, J., Cagua-Ordoñez, J. C., Campuzano-Donoso, M., & Simancas‐Racines, D. (2026) · Nutrients · doi:10.3390/nu18142280
„Battle of Experts“: Spritze versus Sport
Sonnet, M. (2024) · Info Diabetologie · doi:10.1007/s15034-024-4966-2
Management kardiovaskulärer Erkrankungen bei Adipositas
Baessler, A., Zurkan, D., Bischoff, G., Esefeld, K., Hümmelgen, M., Aberle, J., Wienbergen, H., Blüher, M., Werner, N., Müller, O. J., et al. (2026) · Die Kardiologie · doi:10.1007/s12181-026-00813-8 · Cited by 1
Tănăsescu, M., Rosu, A.-M., Mincă, A., Grigorie, M.-M., Timofte, D., & Ionescu, D. (2026) · Life · doi:10.3390/life16050756 · Cited by 1
“Overall, the evidence beyond T2D has helped define the different clinical domains in which these two drug classes are most relevant: SGLT-2 inhibitors mainly in HF and CKD, and GLP-1 receptor agonists mainly in obesity-associated and atherosclerotic CV risk [10,53,54,64,65].”
InfluentialFactors Associated With New-Onset Atrial Fibrillation in Thai Adults with Hypertension
Limpijankit, V., Sasiprapha, T., Teza, H., Pattanateepapon, A., Siriyotha, S., Boonmanunt, S. W., Attia, J. R., & Thakkinstian, A. (2025) · American Journal of Hypertension · doi:10.1093/ajh/hpaf149 · Cited by 1
Medikamentöse Therapie der Adipositas
Malzner, A. (2026) · Journal für Gastroenterologische und Hepatologische Erkrankungen · doi:10.1007/s41971-026-00250-0
EASL-EASD-EASO guidance on the use of resmetirom and semaglutide as MASH-targeted therapy
Tacke, F., Horn, P., Wong, V. W. S., Ratziu, V., Bugianesi, E., Francque, S., Zelber‐Sagi, S., Caussy, C., Roden, M., Gastaldelli, A., et al. (2026) · Journal of Hepatology · doi:10.1016/j.jhep.2026.08.028 · Cited by 4
Murugadoss, K., Venkatakrishnan, A., & Soundararajan, V. (2026) · Biology Methods and Protocols · doi:10.1093/biomethods/bpag043
“…management [8, 9], reduction of major adverse cardiovascular events in patients with obesity and established cardiovascular disease but no diabetes [10], symptomatic improvement in patients with heart failure with preserved ejection fraction and obesity [11], and slowing of kidney disease…”
Pedicino, D., & Liuzzo, G. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag550
Ozempification of Aesthetics: Why Plastic Surgeons Must Lead the GLP-1 Era
Franco, J. (2026) · Aesthetic Surgery Journal · doi:10.1093/asj/sjag060
Tan, K., Hey, P., Vaz, K., & Sinclair, M. J. (2026) · Current Hepatology Reports · doi:10.1007/s11901-026-00723-z
Sasaki, L. S., COSTA, F. G., Martins, A. B., Vieitas, M. S., Lima, A. L. S., & Monteiro, A. M. Z. A. (2024) · Cuadernos de Educación y Desarrollo · doi:10.55905/cuadv16n13-021 · Cited by 1
Blankson, G. A., Acheampong, I. A., Carboo, A. K., Kumi, D. D., Amoah, J., Nawal, A., Djanie, S. N.-A., Prempeh, I., Seidu, A., & Buckner, R. K. (2026) · International Journal of Cardiology Cardiovascular Risk and Prevention · doi:10.1016/j.ijcrp.2026.200681
Comment on: Semaglutide and cardiovascular outcomes in obesity without diabetes
Basolo, A., Fierabracci, P., Salvetti, G., & Santini, F. (2023) · Journal of Endocrinological Investigation · doi:10.1007/s40618-023-02290-2 · Cited by 2
Identifying high-risk combinations of metformin during COVID-19
Dimnjaković, J., Buble, T., Poljičanin, T., Brborović, H., Brađašević, E., & Brborović, O. (2026) · PLoS ONE · doi:10.1371/journal.pone.0343979
“Metformin, SGLT-2 inhibitors and GLP-1 agonists generally have good cardiovascular (CV) safety profile [48–51].”
Treatment Decision-making and Weight Loss Expectations for Current Obesity Treatment
Paknikar, S. S., & Shah, M. (2026) · Current Obesity Reports · doi:10.1007/s13679-026-00691-x
“Due to the presence of obesity and established CAD the preferred agent would be semaglutide, which has been shown to reduce major adverse cardiac events (MACE) in patients living with obesity, with or without diabetes (Table 1) [14 ].”
Obesity, metabolic health status, and adverse outcomes in men and women
Ananda, R. A., Solomon, B. D., Nicholls, S. J., & Ray, K. K. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101556 · Cited by 2
“Improved end-organ hard outcomes using these therapies in individuals with obesity and established ASCVD[17], HF with preserved ejection fraction[18,43], MASH or fibrosis[44,45], and CKD,[46] demonstrate the modifiability of multiple health outcomes resulting from obesity.”
InfluentialAhmed, M. M., Nazari, R., Othman, Z. K., Musa, S. S., Okesanya, O. J., Adebayo, U. O., Branda, F., Elmi, A. H., & Prisno, D. E. L. (2026) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188261472587 · Cited by 2
Obesity medications versus metabolic bariatric surgery: the debate goes on
Tan, T. M.-M. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(26)00124-5
Structural Assumptions in Semaglutide Cost-Effectiveness—Reply
Hennessy, S. S., Khan, S. S., & Kazi, D. S. (2026) · JAMA Cardiology · doi:10.1001/jamacardio.2026.0710
Sex Differences in Cardiovascular-Related Responses to Obesity Treatment
Silver, N., Ghanta, A., Abene, J., Pinto, Y., & Chao, A. M. (2025) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-025-00774-9
Oral semaglutide in HFpEF: Real-world evidence and causal considerations
Catalán, V., Frühbeck, G., & Gómez‐Ambrosi, J. (2025) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2025.07.024
Aberle, J., Lautenbach, A., Meyhöfer, S., Menzen, M., Selig, L., Mai, K., Blüher, M., & Terkamp, C. (2025) · Diabetologie und Stoffwechsel · doi:10.1055/a-2592-8270 · Cited by 2
Gil, F. M. A., Osoro, I. A., Franch‐Nadal, J., & de la Puente, J. B. (2025) · Diabetes práctica · doi:10.52102/diabet/pract.2025.1.art3
Oral semaglutide and survival in heart failure with preserved ejection fraction and type 2 diabetes
Kishimori, T., Kato, T., Iwasaki, Y., Shimada, T., Wada, A., Tani, A., Yamaji, R., Koike, J., Matsumoto, T., Yagi, T., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70433 · Cited by 1
“25 In the STEP-HFpEF and STEP-HFpEF DM trials, once-weekly injectable semaglutide (2.4 mg) showed that sema-glutide led to significant improvements in patient-reported quality of life in patients with HFpEF and obesity, with or without T2D, respectively.”
InfluentialCollaborators, G. U. H. D., Mouhanna, F., Kahn, E., Schmidt, C. A., McHugh, T. A., Baumann, M. M., Kelly, Y. O., Motte‐Kerr, W. L., Cogen, R. M., Dai, X., et al. (2026) · BMC Medicine · doi:10.1186/s12916-026-04795-y · Cited by 1
“This class of drugs also reduced the incidence of comorbidities such as type 2 diabetes [96] and cardiovascular events [97, 98].”
Jurin, I., Gjuras, K., Bešić, D., Jurin, H., Kursar, J., Cvetko, T.-T., Rode, F., Šipić, T., Lišnjić, P., Manola, Š., et al. (2026) · Cardiology · doi:10.1159/000551964
Association Between Glucagon‐Like Peptide‐1 Receptor Agonists and Risk of Arrhythmias
Jaiswal, V., Hanif, M., Goyal, A., Yasmeen, J., Garimella, V., Mashkoor, Y., Vempati, R., Deb, N., NASIR, Y. M., Rajak, K., et al. (2025) · Journal of Arrhythmia · doi:10.1002/joa3.70242 · Cited by 2
“The Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity (SELECT) trial confirmed that semaglutide reduces the risk of major adverse cardiovascular events (MACE) in patients with preexisting CVD and obesity [19].”
The synergistic treatment of heart and kidney disease
Mahfoud, F., Götzinger, F., Kramann, R., Marx, N., & Schwenger, V. (2026) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.m2025.0131 · Cited by 1
Safety of semaglutide on depressive symptoms among people with HIV in routine clinical care
Haidar, L., Ruderman, S. A., Leong, C., Doupe, M. B., Lesko, C. R., Delaney, J. A., Alba, D. L., Drumright, L. N., Fojo, A. T., Fredericksen, R. J., et al. (2026) · AIDS · doi:10.1097/qad.0000000000004598
Bao, W., Xu, J., Nian, W., Pang, P., Wu, W., Huang, Z., Hu, L., Zhang, Q., Pan, W., Gao, X., et al. (2026) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.126.324797 · Cited by 1
Patarroyo-Rodríguez, L., Voort, J. L. V., Kung, S., Brown, S. K., Cavalcanti, S., Ritter, M. J., & Singh, B. (2024) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001939 · Cited by 1
Chen, K., Du, Y., & Zhu, Y. (2025) · Therapeutic Innovation & Regulatory Science · doi:10.1007/s43441-025-00840-9 · Cited by 1
Nastase, I., Iordachi, T. F. D., Gurzun, M., Guțu, C., & Sârbu, N. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15103909 · Cited by 1
Mitochondrial remodeling as a effector of glp-1 therapy in obesity and diabetes: review
Alhindi, Y. Z. (2026) · Journal Of Advanced Pharmacy Education And Research · doi:10.51847/bfye5lnqza
Efficacy of glucagon-like-peptide-1 agonists for weight loss in adults with CHD
Varghese, P., Elder, R. W., Vinocur, J. M., Spatz, E. S., Shabanova, V., McCollum, S., Harper, M., & Pastor, T. A. (2026) · Cardiology in the Young · doi:10.1017/s1047951126113109 · Cited by 1
“They have been shown to have a positive effect on glycaemic control, weight loss, 1 – 3 and cardio-vascular health, 4,5 but their popularity has largely been driven by their effect on weight reduction.”
Lederer, E. D. (2025) · Nephrology Self-Assessment Program · doi:10.58483/nsap.00382025
Gillikin, A. P., Lee, Y., Varney, C., Dang, J. T., Tsung, A., Nimeri, A. A., & Shin, T. H. (2026) · EClinicalMedicine · doi:10.1016/j.eclinm.2026.104033 · Cited by 3
“41 47 The attenuated effect size observed in our post-surgical cohort is biologically plausible, as the incremental cardiovascular benefit of incretin-based therapy may be smaller in a population that has already undergone the metabolic improvements conferred by bariatric surgery.”
InfluentialThe ‘astounding’ rise of semaglutide — and what’s next for weight-loss drugs
Nogrady, B. (2026) · Nature · doi:10.1038/d41586-026-00228-1
Would a weekly shot be enough to solve the obesity problem? a new denial of a complex reality
Duparc, A., Terral, P., & Lairez, O. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf002
Metadata
- Authors
- Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., Lingvay, I., Oral, T. K., Michelsen, M. M., Plutzky, J., Tornøe, C. W., & Ryan, D. H.
- Affiliations
- Cleveland Clinic (US)
- From the Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland (A.M.L.); Novo Nordisk, Søborg, Denmark (K.B.-F., S.E., S.H.-L., G.K.H., T.K.O., M.M.M., C.W.T.); the Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh (H.M.C.), and the National Institute for Cardiovascular Outcomes Research, University College London, London (J.D.) — both in the United Kingdom; the Department of Biostatistics, University of Washington (S.S.E.), and the Department of Medicine, VA Puget Sound Health Care System and University of Washington (S.E.K.) — both in Seattle; the Department of Vascular Medicine, Academic Medical Center, Amsterdam (G.K.H.); the Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago (R.F.K.); the Department of Internal Medicine (Endocrinology Division) and Peter O’Donnell Jr. School of Public Health, University of Texas Southwestern Medical Center, Dall...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-12-14
- Volume
- 389
- Issue
- 24
- Pages
- 2221-2232
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4388592674
- Cited by
- 3,236
- References
- 42
- Citations by year
- 2026: 1298 · 2025: 1114 · 2024: 796 · 2023: 25
- FWCI
- 658.51
- Type
- journal article
- Language
- en
- Open access
- green
- discovery.ucl.ac.uk
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
- Dspace Repository (Marmara Üniversitesi) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Funders
- Novo Nordisk Pharma
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- semaglutide, obesity, overweight, cardiovascular outcomes, GLP-1 receptor agonists, pre-existing cardiovascular disease, myocardial infarction, stroke, cardiovascular mortality, adverse events, body mass index, weight loss, SGLT2 inhibitors, SELECT trial, drug safety and efficacy, non-diabetic patients, drug discontinuation, time to first event
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Cardiovascular Agents, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Double-Blind Method, Glucagon-Like Peptides, Humans, Hypoglycemic Agents, Myocardial Infarction, Obesity, Stroke, Overweight
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
